Introduction: Radiation-induced medulloblastoma is exceedingly rare. Four cases of adult medulloblastoma were previously reported to have occurred following whole brain or craniospinal irradiation. Development of systemic malignancies secondary to proton beam therapy is extremely uncommon, with a lifetime risk lower than 1 %. Methods and Results: A 39-year-old woman presented with gait instability and a right cerebellar mass following an 8-year latency period post-fractionated proton therapy for an acoustic neuroma. To date, no cases of new onset medulloblastoma have been reported following proton beam therapy. The differential diagnosis by imaging studies includes brain radiation necrosis. Conclusion: The current report highlights the possible, although rare, risks and complications associated with proton beam radiation. Further studies are needed to address issues related to the management and treatment of radiationinduced medulloblastomas.
Introduction
Medulloblastomas occur infrequently in adults and account for approximately 1 % of adult central nervous system tumors. Adult medulloblastomas are believed to behave clinically similar to childhood tumors with an approximately equal 5-year overall survival rate of 70 % comparable to similar survival rates in childhood medulloblastomas [1, 2] . However, longer follow-up periods have revealed a decreased 20-year overall survival rate for adult (38 %) versus pediatric medulloblastomas (51 %) [3] .
Recognition of radiation-induced medulloblastoma is essential, due to their aggressive clinical behavior. Furthermore, the expected benefit from an additional full course of radiation therapy is minimal because of the high and fatal complication risks. Successful therapy of medulloblastoma requires a multidisciplinary approach involving surgery, radiation therapy, and chemotherapy with a consequent risk of secondary complications.
Four cases of radiation-induced medulloblastoma following whole-brain irradiation have been previously reported [4] [5] [6] . The most prevalent secondary brain tumors reported postradiotherapy are high-grade gliomas following gamma-knife radiosurgery [7] [8] [9] . Generally, the development of malignancies secondary to proton beam therapy is rare (<1 % lifetime risk); the most commonly induced cancers include lung and thyroid cancers, leukemias and urothelial carcinoma [10, 11] . No cases of medulloblastomas were reported to have occurred following a course of proton beam therapy. Herein, the first case of adult medulloblastoma following proton beam therapy for an "acoustic neuroma" is described. Radiation necrosis, an integral differential diagnosis in the current clinical scenario, is to be excluded radiologically and if clinically indicated, histopathologically.
Case report
The patient is a 39-year-old female presenting with new onset headache and gait instability. Previous medical history includes a radiological diagnosis of a right acoustic neuroma treated 8 years earlier with 54 Gy of fractionated proton beam radiotherapy in 30 sessions at Loma Linda University, California, USA. The patient is not known to have neurofibromatosis type-2 (NF2), schwannomatosis or Carney complex. There is no history of familial brain tumors. Brain magnetic resonance imaging (MRI) performed on admission revealed a residual right cerebellopontine angle small extra-axial lesion, radiologically defined as a vestibular schwannoma. An ill-defined T2 hyperintense right lateral cerebellar lesion was also noted, with contrast enhancement and significant surrounding edema extending to the contralateral side (Fig. 1) . The patient developed progressive symptoms of increased intracranial pressure. A decompressive suboccipital craniotomy was performed. Microscopy revealed dense sheets of large anaplastic cells with focal formation of centrally necrotic rosette-like structures (Fig. 2) . The anaplastic cells exhibited increased nuclear to cytoplasmic ratio and prominent nucleoli. Scattered areas of perivascular pseudorosettes were also identified. Sheets of anaplastic cells involved the cerebellar molecular layer, invading, at multiple locations, cerebellar white matter, and leptomeninges. The anaplastic cells were positive for synaptophysin, focally stained for glial fibrillary acidic protein (GFAP), and expressed p53 (up to 30 % of cells; Fig. 3 ). Proliferative index (Ki-67) was elevated, approximately 40 %. A diagnosis of anaplastic/large cell medulloblastoma was established, supported by the cellular morphology and immunohistochemical profile. The patient opted to receive further treatment at an outside hospital. Follow-up information from the treating physician outlined increased neurological deficit 5 months postoperatively. The patient subsequently was lost to follow-up.
Discussion
The lifetime risk of brain malignancy due to scattered external neutrinos from proton beam therapy is reported to be 0.05 % for males and 0.10 % for females [12] . The highest reported lifetime risk for lung carcinoma treatment is 3.55 % for females and 1.53 % for males. These studies are purely based on extrapolations of the amount of neutrinos emitted from proton beam therapy. Tumors treated with proton beam therapy include ocular (uveal) melanoma, sarcomas of the skull base and spine, paranasal sinus, nasal and nasopharyngeal tumors, benign meningioma, carcinoma of the prostate and pediatric malignancies such as neuroblastoma, central nervous system primitive neuroectodermal tumor, and medulloblastoma [13] . Analogous to conventional photon radiation therapy, the mechanism of proton beam therapy effect on tumor cells leads to the production of free radicals, followed by DNA damage and activation of p53, caspase-9 and caspase-3 pathways with eventual tumor cell death and apoptosis [14] . The late effects and complications of radiation on normal tissues can also trigger capillary regeneration in response to significant hypoxia and cellular stress [15] [16] [17] .
Widely accepted principles of radiation oncogenesis published by Cahan et al. [18] state the following: (1) a latency period is required between radiation delivery and tumor development; (2) The newly diagnosed tumor should occur within the irradiated field; (3) The new tumor must be histologically unique in comparison to the original tumor; (4) Radiological imaging should confirm the absence of the new tumor at the time of original tumor diagnosis; and (5) the patient should not be genetically predisposed to develop a new tumor. The radiation dose used in all reported cases ranged from 24 to 55 Gy with a latency period of 8-33 years (Table 1 ). In the current report, the radiation field covered part of the posterior fossa, the new tumor histopathologic subtype was different from the originally treated vestibular schwannoma and there was an 8- Although the risk of developing malignancy secondary to proton beam radiotherapy exceeds the incidence of malignancy in a healthy cohort population, one cannot exclude the possibility of a de novo tumor unrelated to radiation exposure. However, there was no evidence of predisposing risk factors, including genetic, for the development of malignant neural tumors in this patient and no known clinical or family history of nervous system tumors or NF2. Although the diagnosis of NF2 increases the incidence of secondary malignancy by 0.5 %, the additional factor of radiotherapy for acoustic neuroma increases the risk of secondary malignancies by 12-fold up to a 6 % incidence [19] . Similar to retinoblastoma patients with post-radiotherapy development of secondary malignancies, the mechanism of increased post-radiotherapy malignancy in NF2 is believed to be due to allelic inactivation of NF2 and p53 genes [20] . However, one report found no evidence of secondary malignancies post-radiotherapy for acoustic neuromas in NF2 patients with a median follow-up period of 53 months [21] .
One of the main clinicoradiologic differential diagnoses is delayed cerebellar radiation-induced necrosis. This is an uncommon side effect of cranial irradiation, originally described in irradiated extracranial lesions [22] . The development of radionecrosis is inversely related to fraction number and directly proportional to the total dose and dose per fraction [23] . The concept of receiving a full radiation course with a conventional fraction size should practically have a lower risk of secondary malignancies and complications. A mean interval of 1 year is reported between radiation and the time of radiation-induced necrosis for patients receiving more than 50 Gy; however, there are reports of radionecrosis occurring as early as 3 months or as late as 19 years post-radiotherapy [23] . Clinically, the presentation is variable including headache, seizures, personality changes, and neurologic deficits. Delayed cerebral radionecrosis on imaging may appear as an aggressive lesion due to breakdown of the blood-brain barrier. Large lesions may appear as enhancing foci, surrounded by nonenhancing necrotic areas. Perfusion MRI may aid in differentiating radionecrosis from tumor [24] . MR spectroscopy distinguishes tumors from radiation necrosis based on an increased tumoral choline peak [25] , while positron emission tomography with F-18 fluorodeoxyglucose measures changes in glucose uptake. The nonspecific MRI images of a diffusely contrast-enhancing lesion with surrounding edema, combined with the history of previous radiotherapy, expanded the radiological differential diagnosis to include radiation necrosis. The pathology of radiation necrosis is characterized by fibrinoid necrosis and hyalinization of the blood vessels with surrounding parenchymal necrosis and gliosis. Therefore, since both lesions may appear radiologically similar, histopathology remains the preferred diagnostic tool.
Comparison of intensity-modulated radiotherapy or photon therapy with intensity-modulated proton therapy for childhood medulloblastomas yields an estimated secondary cancer lifetime risk of 54-71 versus 9 %, respectively, following a radiation dose of 36 Gy [26] . This implies that proton radiotherapy is relatively safer with respect to overall secondary complications in comparison to photon radiotherapy. The estimated 3-year risk of secondary malignancy ranges from 0.43 to 0.76 % for photon radiotherapy and 0.05 % for proton radiotherapy [27] . The incidence of adult medulloblastoma is reported to be 0.5 per million per year [28] rendering proton beam radiotherapy-induced medulloblastoma more probable than a de novo tumorigenic event.
The prognosis of radiation-induced medulloblastoma is unfortunately dismal. The current case showed evidence of focal glial differentiation, a finding presumed to impart a worse prognosis [29] . The prognostic value of GFAP expression in medulloblastomas is controversial with discrepant findings reporting either a negative [30] or a positive prognostic impact [31] . GFAP expression has also been attributed merely to entrapped astrocytes [32] . Despite the correlation of high-risk metastatic disease in pediatric medulloblastomas with increased p53 expression [33] , the prognostic value remains controversial [34] . Furthermore, a decreased radiation response is detected in p53-inactivated medulloblastoma cell lines [35] . The treatment of radiationinduced medulloblastoma varied from resection to chemotherapy with lomustine and vincristine [36] . One report advocates additional radiotherapy to complement the treatment regimen [6] , provided the patient had an adequate interval to recover from the first radiation dose [37] [38] [39] .
In conclusion, a unique case of proton beam radiotherapyinduced medulloblastoma is described. The relative safety of focused proton beam radiotherapy forms the basis for the management of a well-defined category of vestibular schwannomas. The radiologic differential diagnosis of radiation necrosis is considered; although, in the proper clinical setting, greater than 1-year post-radiotherapy latency time intervals may necessitate a biopsy to exclude a new-onset neoplastic process. RT radiation therapy, DOD died of disease, AWD alive with disease, NA not available
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